Dow Jones-Qiagen Finance board Roland Sackers sees chances of being able to exceed the targeted growth in the core business of comparable 5 percent for 2025. Some markets are currently very volatile, said the manager in a telephone press conference and referred to China and the USA.
In the United States, customers in the public sector are particularly unsettled in the public sector after President Donald Trump took office in view of the new orders every day with regard to research and funding. This stops some customers from investing in the long term, “for example in a device, for example,” said Sackers. For example, because they did not know whether the money will later be enough to pay the consumables in the next few years.
“I think that’s an uncertainty that exists,” said Sackers. However, he assumes that this will stabilize and normalize over time. “Then I think we have the opportunity to grow better and faster,” said Sackers.
For the first quarter he sees no major effects on Qiagen. The test specialist had given the goal on Wednesday, in 2025 in the comparable core business, i.e. adjusted to grow up 5 percent in order to grow recently adjusted. This corresponds to the rate of the second half of 2024. At the same time, the operational margin 2025 is to increase by 150 basis points to over 30 percent.
Qiagen makes almost half of its sales in the United States and less than 5 percent in China.
The consequences of possible US tariffs are difficult to estimate on imports from Europe. Because in Germany it is also produced for the US market, says Sackers.
Contact with the author: [email protected]
DJG/Rio/BRB
(End) Dow Jones Newswires
February 06, 2025 06:00 ET (11:00 GMT)
Selected leverage products on Qiagen
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Qiagen
The lever must be between 2 and 20
Advertising